Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Olympion Medical Center
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01777919CT.gov Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform | — | Not Yet Recruiting | — | — | — |
NCT03363659CT.gov Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme | — | Terminated | — | — | — |
NCT03151772CT.gov Bioavailability of Disulfiram and Metformin in Glioblastomas | — | Terminated | — | — | — |
NCT03034135CT.gov Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma | — | Completed | — | — | — |
NCT02678975CT.gov Disulfiram in Recurrent Glioblastoma | — | Completed | — | — | — |
NCT02770378CT.gov A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma | — | Completed | — | — | — |
NCT02715609CT.gov Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | — | Completed | — | — | — |
NCT01907165CT.gov Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Disulfiram (this asset) | Olympion Medical Center | P2/3 | B · 58 |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Capecitabine | Northwell Health | P2 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Carboplatin | Sichuan Honghe Biotechnology Co., Ltd. | P3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Disulfiram
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P2 | CCC · 52 |
| Breast Neoplasm | — | P2 | CCC · 52 |
| Glioma | — | P2/3 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Disulfiram in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/disulfiram-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →